

**JUBILANT PHARMA LIMITED**  
(Company Registration No. 200506887H)  
(Incorporated in the Republic of Singapore)  
Registered office: 80 Robinson Road, #02-00, Singapore 068898

August 2, 2022

**Singapore Exchange Securities Trading Limited**  
11 North Buona Vista Drive #06-07  
The Metropolis Tower 2  
Singapore 138589

Dear Sirs,

**Subject: Announcement**

We enclose an announcement pertaining to USFDA Audit.

This is for your kind information and records.

Thanking you,

Yours faithfully,  
For Jubilant Pharma Limited

Sd/-  
Shyam S. Bhartia  
Chairman and Managing Director

Encl.: As above



**Jubilant Pharma Ltd.**  
6 Temasek Boulevard, #20-06  
Suntec City Tower Four, Singapore 038986  
Tel.: +65 6235 4129  
[www.jubilantpharma.com](http://www.jubilantpharma.com)

## **Jubilant Pharma announces USFDA completes Audit of its Solid Dosage Manufacturing Facility at Roorkee, India**

**Noida (UP), India, Tuesday, August 2, 2022**

Jubilant Pharma Limited (“The Company”), a wholly-owned subsidiary of Jubilant Pharmova Limited, today announced that the United States Food and Drug Administration (USFDA) has recently concluded audit of its subsidiary Jubilant Generics Limited’s Solid Dosage Formulations facility at Roorkee, India.

The US FDA has issued six observations pursuant to the completion of the audit. The company will submit an action plan on the observations and will engage with US FDA for next steps.

### **About Jubilant Pharma Limited**

Jubilant Pharma Limited (JPL), a Company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage Formulations through five manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. The Company has a team of around 3,500 multicultural people across the globe and is committed to delivering value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally. For more info please visit [www.jubilantpharma.com](http://www.jubilantpharma.com)

### **For Investors**

Vineet V Mayer  
Ph: +91 120 436 1103  
E-mail: [vineet.mayer@jubl.com](mailto:vineet.mayer@jubl.com)

### **Disclaimer**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharma may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.